Ronald P. Taylor focuses on Antibody, Immunology, CD20, Complement system and Antigen. His Antibody study incorporates themes from Molecular biology, Cell biology, Immune system and Virology. His Molecular biology study combines topics from a wide range of disciplines, such as In vitro, Raji cell, Immunoglobulin G, iC3b and Cell killing.
The Rituximab, Monoclonal antibody and Immune complex research Ronald P. Taylor does as part of his general Immunology study is frequently linked to other disciplines of science, such as Immune adherence, therefore creating a link between diverse domains of science. His work deals with themes such as Monoclonal, Chronic lymphocytic leukemia, B cell and Immunotherapy, which intersect with CD20. Specifically, his work in Complement system is concerned with the study of Classical complement pathway.
Ronald P. Taylor mainly investigates Antibody, Immunology, Molecular biology, Monoclonal antibody and Complement system. His Antibody study combines topics in areas such as Biochemistry, DNA, Immune system, Antigen and Cell biology. His research in Molecular biology focuses on subjects like Immune complex, which are connected to Red blood cell.
His Monoclonal antibody research includes elements of Complement receptor 1, In vitro, Virology and Complement receptor. His work carried out in the field of Complement system brings together such families of science as Cytotoxic T cell and Cytotoxicity. The various areas that Ronald P. Taylor examines in his CD20 study include Trogocytosis, Complement-dependent cytotoxicity, Chronic lymphocytic leukemia and B cell.
Ronald P. Taylor mainly focuses on Antibody, Complement system, Cell biology, Immunology and Cancer research. Ronald P. Taylor has included themes like Antigen and Cytotoxicity in his Antibody study. His Complement system study contributes to a more complete understanding of Immune system.
His Immunology research is multidisciplinary, relying on both Anemia and Kidney disease. His study looks at the relationship between Complement-dependent cytotoxicity and topics such as Molecular biology, which overlap with Intracellular. The study incorporates disciplines such as Cancer, Cytotoxic T cell and Chronic lymphocytic leukemia in addition to Monoclonal antibody.
Complement system, Antibody, Immunology, Monoclonal antibody and Cytotoxicity are his primary areas of study. His research in Complement system intersects with topics in Virology, Complement-dependent cytotoxicity, B cell, Cell biology and Cytotoxic T cell. As part of his studies on Antibody, he often connects relevant areas like Pharmacology.
His research in Immunology is mostly concerned with Antibody-dependent cell-mediated cytotoxicity. His Monoclonal antibody research focuses on subjects like Antigen, which are linked to Monoclonal and Cancer cell. His Cytotoxicity study which covers Classical complement pathway that intersects with Cellular immunity, Molecular biology and Effector.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mechanisms of killing by anti-CD20 monoclonal antibodies.
Martin J. Glennie;Ruth R. French;Mark S. Cragg;Ronald P. Taylor.
Molecular Immunology (2007)
Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia
Adam D. Kennedy;Paul V. Beum;Michael D. Solga;David J. DiLillo.
Journal of Immunology (2004)
Complement is activated by IgG hexamers assembled at the cell surface.
Christoph A. Diebolder;Frank J. Beurskens;Rob N. de Jong;Roman I. Koning.
Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
G D Ross;W J Yount;M J Walport;J B Winfield.
Journal of Immunology (1985)
Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Andrew W. Pawluczkowycz;Frank J. Beurskens;Paul V. Beum;Margaret A. Lindorfer.
Journal of Immunology (2009)
The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes
Paul V. Beum;Adam D. Kennedy;Michael E. Williams;Margaret A. Lindorfer.
Journal of Immunology (2006)
Physiological and pathological aspects of circulating immune complexes.
Jürg A. Schifferli;Ronald P. Taylor.
Kidney International (1989)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao Yi Wang;Emilian Racila;Ronald P. Taylor;George J. Weiner.
An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition and killing of CD20+ cells by Rituximab
Adam D. Kennedy;Michael D. Solga;Theodore A. Schuman;Amos W. Chi.
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.
Ronald P Taylor;Margaret A Lindorfer.
Current Opinion in Immunology (2008)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: